Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
- PMID: 29753700
- PMCID: PMC5984248
- DOI: 10.1016/S1470-2045(18)30242-0
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
Abstract
Background: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines.
Methods: In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts (International Cancer Genome Consortium [ICGC] PedBrain, Medulloblastoma Advanced Genomics International Consortium [MAGIC], and the CEFALO series) and from prospective cohorts from four clinical studies (SJMB03, SJMB12, SJYC07, and I-HIT-MED). Whole-genome sequences and exome sequences from blood and tumour samples were analysed for rare damaging germline mutations in cancer predisposition genes. DNA methylation profiling was done to determine consensus molecular subgroups: WNT (MBWNT), SHH (MBSHH), group 3 (MBGroup3), and group 4 (MBGroup4). Medulloblastoma predisposition genes were predicted on the basis of rare variant burden tests against controls without a cancer diagnosis from the Exome Aggregation Consortium (ExAC). Previously defined somatic mutational signatures were used to further classify medulloblastoma genomes into two groups, a clock-like group (signatures 1 and 5) and a homologous recombination repair deficiency-like group (signatures 3 and 8), and chromothripsis was investigated using previously established criteria. Progression-free survival and overall survival were modelled for patients with a genetic predisposition to medulloblastoma.
Findings: We included a total of 1022 patients with medulloblastoma from the retrospective cohorts (n=673) and the four prospective studies (n=349), from whom blood samples (n=1022) and tumour samples (n=800) were analysed for germline mutations in 110 cancer predisposition genes. In our rare variant burden analysis, we compared these against 53 105 sequenced controls from ExAC and identified APC, BRCA2, PALB2, PTCH1, SUFU, and TP53 as consensus medulloblastoma predisposition genes according to our rare variant burden analysis and estimated that germline mutations accounted for 6% of medulloblastoma diagnoses in the retrospective cohort. The prevalence of genetic predispositions differed between molecular subgroups in the retrospective cohort and was highest for patients in the MBSHH subgroup (20% in the retrospective cohort). These estimates were replicated in the prospective clinical cohort (germline mutations accounted for 5% of medulloblastoma diagnoses, with the highest prevalence [14%] in the MBSHH subgroup). Patients with germline APC mutations developed MBWNT and accounted for most (five [71%] of seven) cases of MBWNT that had no somatic CTNNB1 exon 3 mutations. Patients with germline mutations in SUFU and PTCH1 mostly developed infant MBSHH. Germline TP53 mutations presented only in childhood patients in the MBSHH subgroup and explained more than half (eight [57%] of 14) of all chromothripsis events in this subgroup. Germline mutations in PALB2 and BRCA2 were observed across the MBSHH, MBGroup3, and MBGroup4 molecular subgroups and were associated with mutational signatures typical of homologous recombination repair deficiency. In patients with a genetic predisposition to medulloblastoma, 5-year progression-free survival was 52% (95% CI 40-69) and 5-year overall survival was 65% (95% CI 52-81); these survival estimates differed significantly across patients with germline mutations in different medulloblastoma predisposition genes.
Interpretation: Genetic counselling and testing should be used as a standard-of-care procedure in patients with MBWNT and MBSHH because these patients have the highest prevalence of damaging germline mutations in known cancer predisposition genes. We propose criteria for routine genetic screening for patients with medulloblastoma based on clinical and molecular tumour characteristics.
Funding: German Cancer Aid; German Federal Ministry of Education and Research; German Childhood Cancer Foundation (Deutsche Kinderkrebsstiftung); European Research Council; National Institutes of Health; Canadian Institutes for Health Research; German Cancer Research Center; St Jude Comprehensive Cancer Center; American Lebanese Syrian Associated Charities; Swiss National Science Foundation; European Molecular Biology Organization; Cancer Research UK; Hertie Foundation; Alexander and Margaret Stewart Trust; V Foundation for Cancer Research; Sontag Foundation; Musicians Against Childhood Cancer; BC Cancer Foundation; Swedish Council for Health, Working Life and Welfare; Swedish Research Council; Swedish Cancer Society; the Swedish Radiation Protection Authority; Danish Strategic Research Council; Swiss Federal Office of Public Health; Swiss Research Foundation on Mobile Communication; Masaryk University; Ministry of Health of the Czech Republic; Research Council of Norway; Genome Canada; Genome BC; Terry Fox Research Institute; Ontario Institute for Cancer Research; Pediatric Oncology Group of Ontario; The Family of Kathleen Lorette and the Clark H Smith Brain Tumour Centre; Montreal Children's Hospital Foundation; The Hospital for Sick Children: Sonia and Arthur Labatt Brain Tumour Research Centre, Chief of Research Fund, Cancer Genetics Program, Garron Family Cancer Centre, MDT's Garron Family Endowment; BC Childhood Cancer Parents Association; Cure Search Foundation; Pediatric Brain Tumor Foundation; Brainchild; and the Government of Ontario.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5984248/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5984248/bin/gr2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5984248/bin/gr3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5984248/bin/gr4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5984248/bin/gr5.gif)
Comment in
-
Genetic predisposition to medulloblastomas: just follow the tumour genome.Lancet Oncol. 2018 Jun;19(6):722-723. doi: 10.1016/S1470-2045(18)30289-4. Epub 2018 May 9. Lancet Oncol. 2018. PMID: 29753702 No abstract available.
-
Study Reveals Germline Genetics of Medulloblastoma.Cancer Discov. 2018 Aug;8(8):OF7. doi: 10.1158/2159-8290.CD-NB2018-079. Epub 2018 Jun 22. Cancer Discov. 2018. PMID: 29934315
Similar articles
-
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1. Lancet Oncol. 2018. PMID: 30392813 Free PMC article.
-
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22. Lancet Oncol. 2017. PMID: 28545823 Free PMC article.
-
Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.Lancet Oncol. 2018 Jun;19(6):768-784. doi: 10.1016/S1470-2045(18)30204-3. Epub 2018 May 16. Lancet Oncol. 2018. PMID: 29778738 Free PMC article. Clinical Trial.
-
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. Acta Neuropathol. 2016. PMID: 27040285 Free PMC article. Review.
-
Medulloblastoma and other neoplasms in patients with heterozygous germline SUFU variants: A scoping review.Am J Med Genet A. 2024 Jun;194(6):e63496. doi: 10.1002/ajmg.a.63496. Epub 2024 Jan 28. Am J Med Genet A. 2024. PMID: 38282294 Review.
Cited by
-
The Molecular Detection of Germline Mutations in the BRCA1 and BRCA2 Genes Associated with Breast and Ovarian Cancer in a Romanian Cohort of 616 Patients.Curr Issues Mol Biol. 2024 May 12;46(5):4630-4645. doi: 10.3390/cimb46050281. Curr Issues Mol Biol. 2024. PMID: 38785549 Free PMC article.
-
Developmental origins shape the paediatric cancer genome.Nat Rev Cancer. 2024 Jun;24(6):382-398. doi: 10.1038/s41568-024-00684-9. Epub 2024 May 2. Nat Rev Cancer. 2024. PMID: 38698126 Review.
-
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.J Hematol Oncol. 2024 Apr 29;17(1):26. doi: 10.1186/s13045-024-01547-4. J Hematol Oncol. 2024. PMID: 38685107 Free PMC article.
-
Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?Front Mol Neurosci. 2024 Mar 13;17:1268038. doi: 10.3389/fnmol.2024.1268038. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38544524 Free PMC article. Review.
-
The evolutionary impact of childhood cancer on the human gene pool.Nat Commun. 2024 Feb 29;15(1):1881. doi: 10.1038/s41467-024-45975-9. Nat Commun. 2024. PMID: 38424437 Free PMC article.
References
-
- Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G. Mutations in the human homologue of the drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1997;57:2581–2585. - PubMed
-
- Taylor MD, Liu L, Raffel C. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31:306–310. - PubMed
-
- Li FP, Fraumeni JF. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969;43:1365–1373. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 HL007901/HL/NHLBI NIH HHS/United States
- R01 CA159859/CA/NCI NIH HHS/United States
- U01 CA184898/CA/NCI NIH HHS/United States
- P30 CA021765/CA/NCI NIH HHS/United States
- A17197/CRUK_/Cancer Research UK/United Kingdom
- 001/WHO_/World Health Organization/International
- 22492/CRUK_/Cancer Research UK/United Kingdom
- 336045/ERC_/European Research Council/International
- R01 CA109467/CA/NCI NIH HHS/United States
- R01 CA148699/CA/NCI NIH HHS/United States
- U54 HD090255/HD/NICHD NIH HHS/United States
- P01 CA096832/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous